Is NCT05653258 recruiting in Los Angeles, CA?

Yes, NCT05653258 is currently recruiting participants at its Los Angeles, CA location. This obesity clinical trial is actively enrolling qualified participants.

How do I join the obesity clinical trial in Los Angeles?

To join this clinical trial in Los Angeles, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Los Angeles clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Obesity Clinical Trial in Los Angeles, CA

About This Obesity Study in Los Angeles

All participants will undergo baseline biopsies of subcutaneous abdominal adipose tissue for cellular/molecular profiling via snRNA-seq and metabolic/physiological assessments (insulin sensitivity, glucose tolerance, and β-cell function). Older obese participants will be randomized into three arms: lifestyle intervention (n=24), senolytics (n=24), or placebo (n=24).

Sponsor: Cedars-Sinai Medical Center

Who Can Participate

Inclusion Criteria

Age: younger lean group 18-30 years with BMI 18.5-24.9 kg/m2; younger obese group 18-30 with BMI 30.0 -39.9; older obese group ≥ 65 years with BMI 30.0-39.9

All races and ethnic groups

Community dwelling

Sedentary (≤1.5 h of exercise per week)

Nondiabetic (fasting plasma glucose \< 126 mg/dl, 2-h glucose during oral glucose tolerance test (OGTT) \< 140mg/dl, and A1c \< 6.5%

For all female participants who are women of childbearing potential (WOCBP), who are not pregnant or breast feeding, at least one of the following conditions must apply: A documented hysterectomy, bilateral salpingectomy, or bilateral oophorectomy Use of a contraceptive method that is highly effective (with a failure rate of \<1% per year), preferably with low user dependency (implantable progesterone-only hormone contraception, intrauterine hormone releasing system, bilateral tubal occlusion, vasectomized partner) during the intervention period of the study and for at least 30 days after the last dose of study intervention to eliminate any reproductive safety risk of the study drug. Use of a contraceptive method that is highly effective (with a failure rate of \<1% per year), with high user dependency, (oral/intravaginal/injectable combined estrogen and progesterone contraception, oral/injectable progesterone only hormone contraception, sexual abstinence) during the intervention period and for at least 30 days after the last dose of study intervention to eliminate any reproductive safety risk of the study drug. In addition to the highly effective methods: male or female condom with or without spermicide; cervical cap, diaphragm, or sponge with spermicide; a combination of male condom with either cervical cap, diaphragm, or sponge with spermicide.

ECG value after 10 minutes of resting in the supine position in the following ranges: 120ms\<PR\<220ms: QRS\<120ms; QTc\<430ms for males and QTc\<450ms for females and normal ECG tracing, unless the investigator considers the ECG abnormality to be not clinically relevant.

Exclusion Criteria

Diabetes, clinically diagnosed or HbA1c \> 6.5% and/or fasting plasma glucose \> 126 mg/dl and/or use of anti-diabetic medications.

Participating in \> 1.5 h of structured exercise/week

Unstable weight (\>3% change in last 3 months)

Neurological, musculoskeletal, or other conditions that may limit subject's ability to complete study physical assessment and training

Active autoimmune/inflammatory disease including: rheumatoid arthritis, multiple sclerosis, systemic lupus erythematous, inflammatory bowel disease

Laboratory parameters outside the normal range:

impaired kidney function (eGFR \< 30ml/min/1.73m² as calculated by the CKD-EPI equation);

impaired liver function (AST or ALT level \> 2 times upper limit of normal (ULN);

total Bilirubin level \> 1.5 times ULN;

TSH \> 1.5 times ULN or \< lower limit of normal (LLN);

Hemoglobin \<10.0 g/dl; Platelets \<125,000 cell/mm³;

Platelets \< 125,000 cell/mm³

Prothrombin time (PT) \> 1.0 times ULN

Partial prothrombin time (PTT) \> 1.0 times ULN.

Active gastrointestinal disease; coagulopathy; GI bleed within 6 months

Clinically significant heart disease (e.g. NYH Classification \>II; ischemia)

Peripheral vascular disease (claudication)

QTc prolongation \>45 msec

Use of anti-arrhythmic medications known to cause QTc prolongation, anti-platelet or anti-coagulant medication (see section 5.3)

Use of quinolone antibiotics or any other drugs that may prolong the QTc interval (see section 5.3)

Pulmonary disease (COPD), severe asthma or exercise-induced asthma

Recent systemic or pulmonary embolus

Uncontrolled blood pressure (systolic BP\>170, diastolic BP\>95 mmHg)

Smoking, alcohol use (history of regular alcohol consumption exceeding 7 drinks/week for female participants or 14 drinks/week for male participants. 1 drink = 5 ounces \[150ml\] of wine or 12 ounces \[360ml\] of beer or 1.5 ounces \[45ml\] of hard liquor) or recreational drug use (other than marijuana)

Pregnant or breastfeeding

Postmenopausal women new (within 6 months) to systemic hormone replacement therapy

Previous bariatric surgery

History of stroke with motor disability

Recent (3 years) treated cancer other than basal cell carcinoma

Acute or chronic infection

Medication that might interfere with metabolic studies (weight loss medication, systemic steroids, immunosuppressants) within 6 months (see section 5.3)

Potentially senolytic agents within the last 6 months: fisetin, quercetin, luteolin, dasatinib, piperlongumine, or navitoclax (see section 5.3)

History of allergy to dasatinib, quercetin and/or lidocaine.

Concurrent enrollment in another interventional trial.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Los Angeles?

Yes, this clinical trial (NCT05653258) has an active research site in Los Angeles, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Obesity Treatment Options in Los Angeles, CA

If you're searching for obesity treatment options in Los Angeles, CA, this clinical trial (NCT05653258) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Los Angeles research site is actively enrolling participants for this phase 2/3 clinical trial. You'll receive care from experienced obesity specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all obesity clinical trials near you to find additional studies recruiting in your area.

Obesity Clinical Trial in Los Angeles, CA

Expert Care in Los Angeles

IRB Approved

No-Cost Care

Apply for This Los Angeles Location

Why Participate?

Simple Process